Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
Study Summary
The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
Eligible Conditions
- Bladder Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Sensitivity and Specificity of UriFind assay in detecting early stage Bladder Cancer
Trial Design
1Treatment groups
Experimental Treatment
Group I: Clinical Validation GroupExperimental Treatment1 Intervention
Patients with suspected bladder cancer (including hematuria, inflammatory bladder, suspicious ultrasound results)
Find a Location
Who is running the clinical trial?
AnchorDx Medical Co., Ltd.Industry Sponsor
5 Previous Clinical Trials
16,710 Total Patients Enrolled
PPsanalyticsLead Sponsor
1 Previous Clinical Trials
500 Total Patients Enrolled
Specialty NetworksUNKNOWN
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger